Clinical trials: Azacitidine
Engraft Failure, Relapse
Outcomes of Patients After Allo-HSCT With Decitabine and NAC
The investigators will conduct this prospective and randomized clinical trial, to evaluate the hematopoietic reconstitution, GVHD and relapse rate of patients after allo-HSCT with decitabine containing conditional regimen and NAC…
- Conditions
- Engraft Failure, Relapse, GVHD
- Trial name
- NCT04945096
- Testing
- decitabine, Acetylcysteine, Semustine
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid leukemia (AML) or acute…
- Conditions
- Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
- Trial name
- NCT06177067
- Testing
- Revumenib, Venetoclax, Azacitidine
- Where
- 10 sites in United States
- Volunteers
- 24 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Myeloid Leukemia (AML)
Venetoclax TDM in Newly Diagnosed AML: Exposure-Response and Prognosis
Venetoclax combined with azacitidine (VEN-AZA) is the current first-line standard of care for newly diagnosed acute myeloid leukemia (AML) patients unfit for intensive chemotherapy.
- Trial name
- ND-AML (NCT07670130)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML
Rencent years have witnessed great progress of the treatment of acute myeloid leukemia (AML). However, most patients have poor outcomes following the currently first-line DA(daunorubicin, cytarabine)/IA(Idarubicin, cytarabine)…
- Trial name
- NCT04248595
- Testing
- Homoharringtonine, Azacitidine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Ge Zheng
Acute Myeloid Leukemia (AML), Cancer
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute Myeloid Leukemia (AML) participants compared to Best Supportive Care (BSC) when…
- Trial name
- VIALE-T (NCT04161885)
- Testing
- Venetoclax, Azacitidine, Best Supportive Care (BSC)
- Where
- 165 sites in United States, Australia and 16 more
- Volunteers
- 465 people
- Sponsor
- AbbVie
Diffuse Large B Cell Lymphoma
A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma
To explore the safety, tolerability and clinical effects of decitabine combined with R±DHAP for patients with replase and refractory Diffuse Large B cell lymphoma.
- Trial name
- NCT03579082
- Testing
- Decitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Mingzhi Zhang
Advanced Cancers, Lymphoma
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
The goal of this clinical research study is to find the highest tolerable dose of azacitidine that can be given with vorinostat, gemcitabine, busulfan, and melphalan, with a stem cell transplant, and with or without rituximab.
- Trial name
- NCT01983969
- Testing
- Azacitidine, Vorinostat, Gemcitabine
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Juvenile Myelomonocytic, JMML
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML).
- Conditions
- Leukemia, Juvenile Myelomonocytic, JMML, JCML, Neurofibromatosis 1
- Trial name
- NCT05849662
- Testing
- Trametinib, Azacitidine, Fludarabine
- Where
- 21 sites in United States
- Volunteers
- 58 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Acute Myeloid Leukemia
Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study is to evaluate the efficacy and safety of venetoclax combined with CACAG regimen in the treatment of newly diagnosed acute myeloid leukemia.
- Trial name
- NCT05659992
- Testing
- azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Acute Myeloid Leukemia (AML), Lisaftoclax
Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
This is a phase II/III, multicenter, randomized, three-arm, open-label, parallel controlled trial. The primary objective of this study is to compare the 2-years OS rate of the LDA, LHAA, and LA regimens in newly diagnosed…
- Trial name
- NCT07651163
- Testing
- Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Lisaftoclax+azacitidine
- Where
- China
- Volunteers
- 450 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Relapse Leukemia
Efficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML
Allogeneic hematopoietic cell transplantation (allo-HCT) is the only treatment that offers a possible cure for relapsed/refractory AML.
- Trial name
- NCT07091006
- Testing
- VAH
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Ruijin Hospital
Thrombocytopenia, Hematologic Diseases
Prospective Study of Patients With Thrombocytopenia Following HSCT
Isolated thrombocytopenia is a common and severe complication of HSCT, which often leads to an increased risk of life-threatening hemorrhage, frequent requirement of platelet transfusions and extended hospital stays, representing…
- Trial name
- NCT02487563
- Testing
- Decitabine, rhTPO, Conventional Treatment
- Where
- China
- Volunteers
- 97 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study is to compare the efficacy and safety of venetoclax combined with CACAG regimen with the traditional "3+7" regimen in the treatment of newly diagnosed acute myeloid leukemia.
- Trial name
- NCT06068621
- Testing
- Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor, "3+7"
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese PLA General Hospital
Leukemia, Acute Myeloid
Epigenetic Reprogramming in Relapse AML
Successful treatment for children and young adults with relapsed acute myeloid leukemia (AML) continues to be a significant challenge.
- Trial name
- NCT02412475
- Testing
- Decitabine, Vorinostat, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Michael Burke
Advanced Cancers
Azacytidine and Valproic Acid in Patients With Advanced Cancers
Primary Objective: 1. To evaluate side effects and maximum tolerated dose of azacitidine and valproic acid in patients with advanced cancer. Secondary Objectives: 1.
- Trial name
- NCT00496444
- Testing
- Azacitidine, Valproic Acid
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Hodgkin Lymphoma
Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma
This is a Phase II clinical trial for Decitabine plus Camrelizumab resistant/relapsed patients with Hodgkin Lymphoma. The purpose is to evaluate the efficacy and safety of the combination therapy of Chidamide plus Decitabine Plus…
- Trial name
- NCT04233294
- Testing
- Chidamide, Camrelizumab, Decitabine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Brain Tumor Recurrent
Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma
The goal of this clinical research study is to establish the safety of direct administration of 5-Azacytidine into the fourth ventricle of the brain or resection cavity in patients with recurrent posterior fossa ependymoma.
- Trial name
- 5-AZA (NCT02940483)
- Testing
- 5-Azacytidine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- The University of Texas Health Science Center, Houston
Adult T-cell Leukemia/Lymphoma
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
ETP-ALL like patients have poor outcomes and prognosis, and the optimal therapeutic approaches are poorly characterized. The goal of this clinical trial is to evaluate the efficacy and safety of the venetoclax combined with…
- Trial name
- NCT07159620
- Testing
- VEN (Venetoclax), Azacitidine (AZA), Chidamide
- Where
- China
- Volunteers
- 27 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia, Maintenance Treatment
The Maintenance Treatment of "ITIVA" in AML Patients
We apply for this clinical study to evaluate the efficacy of "combined recombinant human interference'- α- 1b, interleukin-2, and thalidomide" regimen in obtaining MRD positive AML patients in CR,as well as the efficacy of the…
- Conditions
- Acute Myeloid Leukemia, Maintenance Treatment, Minor Residue Disease, Interferon-α-1b
- Trial name
- NCT06256627
- Testing
- recombinant human interference'- α- 1b, interleukin-2, thalidomide, Venentoclax and Azacitidine
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Henan Cancer Hospital
Response Rate
Low-dose Decitabine for the Treatment of Decreased Donor Chimerism After Allogeneic Stem Cell Transplantation
Decreasing donor chimerism is considered as an early sign of graft failure or relapse in patients undergoing allogeneic stem cell transplantation.
- Trial name
- NCT03663751
- Testing
- Decitabine
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine